The ultrasound imaging technology is revolutionizing cancer diagnosis, offering patients access to better treatment experiences.
FREMONT, CA: Imaging technology is revolutionizing cancer treatment, enabling better outcomes for the patient. Many medical tech organizations have contributed to the imaging sector, and QT Ultrasound is one of the foremost. The company recently announced the launch of a radiation-free, compression-free breast imaging technology for women at its QTbreasthealth imaging centers.
QT Ultrasound launched QTbreasthealth imaging centers in January 2019 to provide an enhanced experience for women with its advanced quantitative transmission (QT) ultrasound technology. The QTbreasthealth network has centers including, Novato in San Jose, Walnut Creek in California, Grand Rapids in Michigan, and Scottsdale in Arizona.
QT Ultrasound is involved in research, development, and commercialization of automated breast imaging systems. The units are designed to produce and transmit high-resolution ultrasound images. The US Food and Drug Administration (FDA) granted a 510(K) clearance for its QTscan. The company also received a $15 million in funding from the National Institutes of Health (NIH) to continue its QT Ultrasound research.
It has conducted clinical trials in prestigious institutions across the U.S. and Europe. Its ongoing trials are hosted at the Marin Breast Health Trial Center in Novato, CA. The QTscan units are accessible at all QTbreasthealth breast imaging centers. The QT Ultrasound Breast Scanner recently received FDA 510 (K) clearance, and can now be used as ultrasonic imaging systems to deliver reflection-mode and transmission-mode images of the breast.
The offerings of the company have granted young women access to the most comprehensive, integrative, and patient-centered technology. The medically advanced screenings for breast health is designed to empower its patients to make more informed patients regarding their treatment journey.
QTbreasthealth will enable women with a family history of breast cancer to make informed decisions regarding their health and wellbeing. Over 50 percent of women have dense breasts and are likely to get false positives during convention mammography tests. In such cases, QTscan offers an excellent follow-up option for women, as it can identify threat areas even in the case of dense breasts.
QTscan is different from screening mammography and other conventional breast imaging techniques. It emits no radiation, exerts no compression, and requires no injections. The company aims to make breast cancer diagnosis more comfortable and more accessible to women. It will enable younger women at high risk of breast cancer to undergo regular screening.